NO985695L - Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt - Google Patents

Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt

Info

Publication number
NO985695L
NO985695L NO985695A NO985695A NO985695L NO 985695 L NO985695 L NO 985695L NO 985695 A NO985695 A NO 985695A NO 985695 A NO985695 A NO 985695A NO 985695 L NO985695 L NO 985695L
Authority
NO
Norway
Prior art keywords
congestive heart
formulation
heart attack
procedure
treating congestive
Prior art date
Application number
NO985695A
Other languages
English (en)
Norwegian (no)
Other versions
NO985695D0 (no
Inventor
John L Mcnay
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO985695D0 publication Critical patent/NO985695D0/no
Publication of NO985695L publication Critical patent/NO985695L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO985695A 1996-06-06 1998-12-04 Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt NO985695L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (2)

Publication Number Publication Date
NO985695D0 NO985695D0 (no) 1998-12-04
NO985695L true NO985695L (no) 1999-02-04

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985695A NO985695L (no) 1996-06-06 1998-12-04 Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt

Country Status (17)

Country Link
EP (1) EP0914128A1 (cs)
JP (1) JP2000511906A (cs)
KR (1) KR20000016406A (cs)
CN (1) CN1226166A (cs)
AU (1) AU3233197A (cs)
BR (1) BR9709546A (cs)
CA (1) CA2256720A1 (cs)
CZ (1) CZ397698A3 (cs)
EA (1) EA199900006A1 (cs)
HU (1) HUP0003885A2 (cs)
IL (1) IL126966A0 (cs)
NO (1) NO985695L (cs)
PL (1) PL330637A1 (cs)
TR (1) TR199802496T2 (cs)
WO (1) WO1997046241A1 (cs)
YU (1) YU55998A (cs)
ZA (1) ZA974978B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DE50009220D1 (de) * 1999-02-01 2005-02-17 Solvay Pharm Gmbh Verwendung von moxonidin zur behandlung nach herzinfarkt
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
BR9709546A (pt) 1999-08-10
AU3233197A (en) 1998-01-05
KR20000016406A (ko) 2000-03-25
JP2000511906A (ja) 2000-09-12
CN1226166A (zh) 1999-08-18
WO1997046241A1 (en) 1997-12-11
IL126966A0 (en) 1999-09-22
HUP0003885A2 (hu) 2001-04-28
TR199802496T2 (xx) 1999-02-22
PL330637A1 (en) 1999-05-24
EP0914128A1 (en) 1999-05-12
CA2256720A1 (en) 1997-12-11
CZ397698A3 (cs) 1999-05-12
EA199900006A1 (ru) 1999-06-24
NO985695D0 (no) 1998-12-04
YU55998A (en) 1999-11-22
ZA974978B (en) 1998-12-07

Similar Documents

Publication Publication Date Title
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
NO971192L (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
ZA88798B (en) Dental anti-plaque and anti-caries agent
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
DE69814394D1 (de) Verwendung von levobupivacain
GB9408775D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
TR199901003T2 (xx) Ast�m tedavisi i�in loratadin ve bir dekonjestan i�eren bile�im.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
WO1996028185A3 (en) Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
SE9603725D0 (sv) New teatment
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
NO20005981L (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B
EP0744176A3 (en) Methods for inhibiting bone loss
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
YU55998A (en) Oral or implant pharmaceutical formulation with controlled release

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application